Read our latest MD Anderson Cancer Center #research with Drs. Vivek Subbiah, MD David S. Hong MD, Meric-Bernstam, Piha-Paul et al on rechallenging the RAF pathway in solid tumors beyond melanoma from our Re-RAFFLE study published with Springer Nature in Molecular Cancer!
rdcu.be/dCAzJ

Talking about updates in the world of melanoma at MOASC summit in NB tomorrow! MOASC

I’ll be talking about exciting updates in world of melanoma treatment and novel therapeutics in research The Angeles Clinic with Inderjit Mehmi Omid Hamid MD Cancer at Cedars-Sinai !

🚨SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research Sarah Cannon Docs AstraZeneca OncoAlert OncoDaily
scri.com/News/SCRI-Anno…

🚨Exciting News in Clinical Trials!
📍Thrilled to announce a groundbreaking - AstraZeneca & Sarah Cannon Docs collaboration ⭐️ Introducing a game-changing shift from Electronic Health Record (EHR) to Electronic Data Capture (EDC)👉 EHR2EDC (E2E) systems for clinical trial…

Can intratumoral oncolytic therapy induce regression of distant mets? Check out this example involving an #LMS patient on trial. #sarcoma Molecular Cancer Therapeutics EpicentRx, Inc. MD Anderson Cancer Center Vivek Subbiah, MD

aacrjournals.org/mct/article/23…

Excited to share our article in Annals of Oncology about Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)!
MD Anderson Cancer Center International Society of Liquid Biopsy
annalsofoncology.org/article/S0923-…

🎄🚨 Exciting Christmas Eve news! Just published in Annals of Oncology ESMO - Eur. Oncology
🎁 Delighted to unwrap our small #PrecisionMedicine present to the scientific & clinical trial community - our latest publication, 'Liquid Biopsy Response Evaluation Criteria in Solid Tumors…

On behalf of the team at Molecular Partners, we wish everyone a happy and healthy holiday season!

Loving this cover story in VCU Alumni magazine about VCU Massey Comprehensive Cancer Center.

2023 was one for the history books, but 2024 is going to be UNlike anything oncology has seen before.

Pleased to share our latest article on why and how drug dose-finding can be tailored to each patient’s risk-benefit trade-offs 👉 journals.sagepub.com/doi/10.1177/17…

Thanks Patrick! We miss ya!

Had the pleasure of showing Dr. Kimryn Rathmell around NIH during her first week. Visiting some inspiring patients at the Children's Inn and touring NIHClinicalCntr were just a few stops on the tour.

This is very nice and thorough overview of the management of AEs from #RET TKIs. Given the high response rates with #RET TKIs, efforts should be made to prevent and manage AEs, some of which are not obvious (eg chylous ascites). RETpositive RET Renegades

Happy to share our collaborative work MD Anderson Cancer Center Mirella Nardo, MD Mohamed A Gouda Maria Cabanillas, MD Dr. Mimi Hu Anna Poullard Mark Zafereo, MD under the amazing mentorship of Vivek Subbiah, MD to develop strategies for mitigating AEs to selective RETi! Cell Reports Medicine
sciencedirect.com/science/articl…

🚨Hot off the press👉Pleased to share the work of our amazing #RET #precisionmedicine team as we review 'Strategies for mitigating adverse events
related to selective RET inhibitors in patients with RET-altered cancers' Cell Cell Reports Medicine Cell Reports
📍Recommendations…

Happy to share our collaborative work MD Anderson Cancer Center Mirella Nardo, MD Mohamed A Gouda Maria Cabanillas, MD Dr. Mimi Hu Anna Poullard Mark Zafereo, MD under the amazing mentorship of Vivek Subbiah, MD to develop strategies for mitigating AEs to selective RETi! Cell Reports Medicine
sciencedirect.com/science/articl…

Fantastic day with colleagues and friends MD Anderson Cancer Center ' #ASH2023 booth and at the President's Reception. Inspired by the many ways our teams are advancing discovery and elevating clinical standards for the betterment of patients around the world. #EndCancer

1️⃣ I recently assisted Dr. Stephanie Goff with a surgery as part of a clinical trial at NIH Clinical Center. The operation was a tumor resection, which is part of the protocol to test the effect of using combo immunotherapy drugs in a patient with metastatic melanoma.

Dr. Mariana Chavez-MacGregor’s overview of the year in review for metastatic breast cancer at #SABCS23 was one of the best overviews I have seen. I know I am biased, but it was truly outstanding. MD Anderson Cancer Center

2️⃣ Dr. Goff & I worked together when I was a surgeon & she was a fellow in surgical oncology at Brigham and Women's Hospital. It's a full circle moment for me to get to now assist her, especially at #NIH !